Furthermore, according to the results of the PAPMET trial,15 cabozantinib is now approved in the first-line treatment of metastatic papillary RCC, a subtype of RCC driving by the MET signaling pathway.29 The gene discussed is MET; the disease is renal cell carcinoma.